M.D. Anderson Cancer Center

CompanyUnited States

M.D. Anderson Cancer Center develops one asset, in phase 3 (anamorelin hydrochloride in non-small cell lung cancer). Mostly small molecule acting on GHSR; based in the United States.

1
Asset
Furthest stage
Phase 3
1,530
Trials
6
Signals

Pipeline

1
  • anamorelin hydrochloride

    Activates ghrelin receptors to stimulate appetite and growth hormone release.

    Phase 3, Small molecule, GHSR, non-small cell lung cancer, cachexia

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms2
  • Trials1,596
  • Deals1
  • Signals12
  • Integrity notices10
  • Similar companies6

Intelligence